Site-Specific conjugation of monomethyl auristatin e to Anti-CD30 antibodies improves their pharmacokinetics and therapeutic index in rodent models

Molecular Pharmaceutics

Volumn 12, Issue 6, 2015, Pages 1863-1871

  Lhospice, F ^a   Bregeon D ^a   Belmant, C ^a   Dennler, P ^b   Chiotellis, A ^c   Fischer, E ^b   Gauthier, L ^a   Boedec A ^a   Rispaud, H ^a   Savard Chambard, S ^a   Represa, A ^a   Schneider, N ^a   Paturel, C ^a   Sapet, M ^a   Delcambre, C ^a   Ingoure, S ^a   Viaud, N ^a   Bonnafous, C ^a   Schibli, R ^b,c   Romagne F ^d  

^a INNATE PHARMA   (France)

^b ETH Zurich   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

ADCETRIS; antibody drug conjugate; CD30; monomethyl auristatin E; site specific modification; transglutaminase

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; GLUTAMINE; IODINE 125; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; VEDOTIN; CAC10-VCMMAE; MONOCLONAL ANTIBODY; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG UPTAKE; EC50; HUMAN; HUMAN CELL; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CHEMISTRY; FEMALE; SCID MOUSE; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MICE; MICE, SCID; OLIGOPEPTIDES; RATS; RATS, WISTAR;

EID: 84930637479     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500666j     Document Type: Article

References (30)

1. Sassoon, I.; Blanc, V. Antibody-drug conjugate (ADC) clinical pipeline: a review Methods Mol. Biol. 2013, 1045, 1-27
2. Lambert, J. M. Drug-conjugated antibodies for the treatment of cancer Br. J. Clin. Pharmacol. 2013, 76, 248-62
3. Beck, A.; Reichert, J. M. Antibody-drug conjugates: present and future mAbs 2014, 6, 15-7
4. Chari, R. V.; Miller, M. L.; Widdison, W. C. Antibody-drug conjugates: an emerging concept in cancer therapy Angew. Chem., Int. Ed. 2014, 53, 3796-827
5. Younes, A.; Yasothan, U.; Kirkpatrick, P. Brentuximab vedotin Nat. Rev. Drug Discovery 2012, 11, 19-20
6. Francisco, J. A.; Cerveny, C. G.; Meyer, D. L.; Mixan, B. J.; Klussman, K.; Chace, D. F.; Rejniak, S. X.; Gordon, K. A.; DeBlanc, R.; Toki, B. E.; Law, C. L.; Doronina, S. O.; Siegall, C. B.; Senter, P. D.; Wahl, A. F. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood 2003, 102, 1458-65
7. Doronina, S. O.; Mendelsohn, B. A.; Bovee, T. D.; Cerveny, C. G.; Alley, S. C.; Meyer, D. L.; Oflazoglu, E.; Toki, B. E.; Sanderson, R. J.; Zabinski, R. F.; Wahl, A. F.; Senter, P. D. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity Bioconjugate Chem. 2006, 17, 114-24
8. Adem, Y. T.; Schwarz, K. A.; Duenas, E.; Patapoff, T. W.; Galush, W. J.; Esue, O. Auristatin antibody drug conjugate physical instability and the role of drug payload Bioconjugate Chem. 2014, 25, 656-64
9. Hamblett, K. J.; Senter, P. D.; Chace, D. F.; Sun, M. M.; Lenox, J.; Cerveny, C. G.; Kissler, K. M.; Bernhardt, S. X.; Kopcha, A. K.; Zabinski, R. F.; Meyer, D. L.; Francisco, J. A. Effects of drug loading on the antitumour activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 2004, 10, 7063-70
10. Shen, B. Q.; Xu, K.; Liu, L.; Raab, H.; Bhakta, S.; Kenrick, M.; Parsons-Reponte, K. L.; Tien, J.; Yu, S. F.; Mai, E.; Li, D.; Tibbitts, J.; Baudys, J.; Saad, O. M.; Scales, S. J.; McDonald, P. J.; Hass, P. E.; Eigenbrot, C.; Nguyen, T.; Solis, W. A.; Fuji, R. N.; Flagella, K. M.; Patel, D.; Spencer, S. D.; Khawli, L. A.; Ebens, A.; Wong, W. L.; Vandlen, R.; Kaur, S.; Sliwkowski, M. X.; Scheller, R. H.; Polakis, P.; Junutula, J. R. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 2012, 30, 184-9
11. Jeffrey, S. C.; Burke, P. J.; Lyon, R. P.; Meyer, D. W.; Sussman, D.; Anderson, M.; Hunter, J. H.; Leiske, C. I.; Miyamoto, J. B.; Nicholas, N. D.; Okeley, N. M.; Sanderson, R. J.; Stone, I. J.; Zeng, W.; Gregson, S. J.; Masterson, L.; Tiberghien, A. C.; Howard, P. W.; Thurston, D. E.; Law, C. L.; Senter, P. D. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology Bioconjugate Chem. 2013, 24, 1256-63
12. Junutula, J. R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D. D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S. P.; Dennis, M. S.; Lu, Y.; Meng, Y. G.; Ng, C.; Yang, J.; Lee, C. C.; Duenas, E.; Gorrell, J.; Katta, V.; Kim, A.; McDorman, K.; Flagella, K.; Venook, R.; Ross, S.; Spencer, S. D.; Lee Wong, W.; Lowman, H. B.; Vandlen, R.; Sliwkowski, M. X.; Scheller, R. H.; Polakis, P.; Mallet, W. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 2008, 26, 925-32
13. Boswell, C. A.; Mundo, E. E.; Zhang, C.; Bumbaca, D.; Valle, N. R.; Kozak, K. R.; Fourie, A.; Chuh, J.; Koppada, N.; Saad, O.; Gill, H.; Shen, B. Q.; Rubinfeld, B.; Tibbitts, J.; Kaur, S.; Theil, F. P.; Fielder, P. J.; Khawli, L. A.; Lin, K. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats Bioconjugate Chem. 2011, 22, 1994-2004
14. Chumsae, C.; Gaza-Bulseco, G.; Liu, H. Identification and localization of unpaired cysteine residues in monoclonal antibodies by fluorescence labeling and mass spectrometry Anal. Chem. 2009, 81, 6449-57
15. Tian, F.; Lu, Y.; Manibusan, A.; Sellers, A.; Tran, H.; Sun, Y.; Phuong, T.; Barnett, R.; Hehli, B.; Song, F.; DeGuzman, M. J.; Ensari, S.; Pinkstaff, J. K.; Sullivan, L. M.; Biroc, S. L.; Cho, H.; Schultz, P. G.; DiJoseph, J.; Dougher, M.; Ma, D.; Dushin, R.; Leal, M.; Tchistiakova, L.; Feyfant, E.; Gerber, H. P.; Sapra, P. A general approach to site-specific antibody drug conjugates Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 1766-71
16. Axup, J. Y.; Bajjuri, K. M.; Ritland, M.; Hutchins, B. M.; Kim, C. H.; Kazane, S. A.; Halder, R.; Forsyth, J. S.; Santidrian, A. F.; Stafin, K.; Lu, Y.; Tran, H.; Seller, A. J.; Biroc, S. L.; Szydlik, A.; Pinkstaff, J. K.; Tian, F.; Sinha, S. C.; Felding-Habermann, B.; Smider, V. V.; Schultz, P. G. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 16101-6
17. Liu, C. C.; Schultz, P. G. Adding new chemistries to the genetic code Annu. Rev. Biochem. 2010, 79, 413-44
18. Zhou, Q.; Stefano, J. E.; Manning, C.; Kyazike, J.; Chen, B.; Gianolio, D. A.; Park, A.; Busch, M.; Bird, J.; Zheng, X.; Simonds-Mannes, H.; Kim, J.; Gregory, R. C.; Miller, R. J.; Brondyk, W. H.; Dhal, P. K.; Pan, C. Q. Site-Specific Antibody-Drug Conjugation through Glycoengineering Bioconjugate Chem. 2014, 25, 510-20
19. Warden-Rothman, R.; Caturegli, I.; Popik, V.; Tsourkas, A. Sortase-tag expressed protein ligation: combining protein purification and site-specific bioconjugation into a single step Anal. Chem. 2013, 85, 11090-7
20. Li, X.; Fang, T.; Boons, G. J. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions Angew. Chem., Int. Ed. 2014, 53, 7179-82
21. Hudak, J. E.; Barfield, R. M.; de Hart, G. W.; Grob, P.; Nogales, E.; Bertozzi, C. R.; Rabuka, D. Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tag Angew. Chem., Int. Ed. 2012, 51, 4161-5
22. Strop, P.; Liu, S. H.; Dorywalska, M.; Delaria, K.; Dushin, R. G.; Tran, T. T.; Ho, W. H.; Farias, S.; Casas, M. G.; Abdiche, Y.; Zhou, D.; Chandrasekaran, R.; Samain, C.; Loo, C.; Rossi, A.; Rickert, M.; Krimm, S.; Wong, T.; Chin, S. M.; Yu, J.; Dilley, J.; Chaparro-Riggers, J.; Filzen, G. F.; ODonnell, C. J.; Wang, F.; Myers, J. S.; Pons, J.; Shelton, D. L.; Rajpal, A. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 2013, 20, 161-7
23. Jeger, S.; Zimmermann, K.; Blanc, A.; Grünberg, J.; Honer, M.; Hunziker, P.; Struthers, H.; Schibli, R. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase Angew. Chem., Int. Ed. 2010, 49, 9995-7
24. Dennler, P.; Schibli, R.; Fischer, E. Enzymatic antibody modification by bacterial transglutaminase Methods Mol. Biol. 2013, 1045, 205-15
25. Dennler, P.; Chiotellis, A.; Fischer, E.; Bregeon, D.; Belmant, C.; Gauthier, L.; Lhospice, F.; Romagne, F.; Schibli, R. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates Bioconjugate Chem. 2014, 25, 569-78
26. Grünberg, J.; Jeger, S.; Sarko, D.; Dennler, P.; Zimmermann, K.; Mier, W.; Schibli, R. DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl PLoS One 2013, 8, e60350
27. Wahl, A. F.; Klussman, K.; Thompson, J. D.; Chen, J. H.; Francisco, L. V.; Risdon, G.; Chace, D. F.; Siegall, C. B.; Francisco, J. A. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkins disease Cancer Res. 2002, 62, 3736-42
28. Ju, M. S.; Jung, S. T. Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics Curr. Opin. Biotechnol. 2014, 30C, 128-39
29. McDonagh, C. F.; Turcott, E.; Westendorf, L.; Webster, J. B.; Alley, S. C.; Kim, K.; Andreyka, J.; Stone, I.; Hamblett, K. J.; Francisco, J. A.; Carter, P. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng., Des. Sel. 2006, 19, 299-307
30. Gorovits, B.; Krinos-Fiorotti, C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake Cancer Immunol. Immunother. 2013, 62, 217-23